<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777422</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-204</org_study_id>
    <nct_id>NCT04777422</nct_id>
  </id_info>
  <brief_title>Defibrotide in Children With High Risk Kawasaki Disease</brief_title>
  <official_title>A Pilot Study to Determine the Safety of Defibrotide in Children With High Risk Kawasaki Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety of defibrotide with IVIG in children with high risk Kawasaki&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with grade III/IV allergic reaction to defibrotide</measure>
    <time_frame>30 days</time_frame>
    <description>All patients will be monitored for allergic reaction probably or definitely related to defibrotide administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with grade III/IV hemorrhage attributable to defibrotide</measure>
    <time_frame>42 days</time_frame>
    <description>All patients will be monitored for hemorrhage probably or definitely related to defibrotide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with improvement in clinical progression/signs of Kawasaki disease</measure>
    <time_frame>42 days</time_frame>
    <description>Patients will have pre and post treatment assessments with imaging and blood tests to monitor clinical signs of Kawasaki disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kawasaki Disease</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Defibrotide 6.25 mg/kg IV q6h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide</intervention_name>
    <description>Defibrotide 6.25 mg/kg IV q6h up to 7 days</description>
    <arm_group_label>Interventional</arm_group_label>
    <other_name>Defitelio®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kawasaki disease presumptive diagnosis defined according AHA criteria;&#xD;
&#xD;
          -  Signed informed consent and patient assent (if applicable)&#xD;
&#xD;
          -  Diagnosis of KD and initiation of defibrotide within 96 hours from the conclusion of&#xD;
             IVIG treatment&#xD;
&#xD;
          -  Age: 0 - 11 years old&#xD;
&#xD;
          -  High risk category defined as patient meeting ≥2 of the following criteria: male, age&#xD;
             &lt;6 months or &gt;8yrs, IVIG-resistance, Fever lasting greater than 10 days, prior to&#xD;
             diagnosis, Coronary artery aneurysms, and/or Laboratory tests indicating worse&#xD;
             systemic inflammation&#xD;
&#xD;
          -  Patients must be ineligible for or refused to participate in the Kawasaki Disease&#xD;
             Comparative Effectiveness (KIDCARE) study.&#xD;
&#xD;
          -  PT and PTT within institutional normal limits&#xD;
&#xD;
          -  Platelet count ≥100,000/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Grade III or IV hemorrhage or active bleeding;&#xD;
&#xD;
          -  Previous Grade II-IV hypersensitivity to defibrotide&#xD;
&#xD;
          -  Current systemic anti-coagulant therapy and/or fibrinolytic therapy, excluding aspirin&#xD;
             (5 mg/kg/dose maximum).&#xD;
&#xD;
          -  Patients on an active experimental trial for Kawasaki disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mitchell Cairo, MD</last_name>
    <phone>914-594-2150</phone>
    <email>mitchell_cairo@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Morris, RN</last_name>
    <phone>914-594-2150</phone>
    <email>erin_morris@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Ferris, MD</last_name>
      <phone>212-305-8509</phone>
      <email>af240@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katrina Golub, MPH</last_name>
      <phone>(212) 342-1562</phone>
      <email>kg2697@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Puneet Bhatla, MD</last_name>
      <email>puneet.bhatla@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mitchell Cairo</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595-1524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Cairo, MD</last_name>
      <phone>914-594-2150</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Morris, RN</last_name>
      <phone>9145942150</phone>
      <email>erin_morris@nymc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marise D'Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordan Milner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Cowles, NP, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edo Schaefer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kawasaki</keyword>
  <keyword>Children</keyword>
  <keyword>Defibrotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

